<i>Helicobacter</i>‐negative gastritis: a distinct entity unrelated to <i>Helicobacter pylori</i> infection

Genta, Robert M.; Sonnenberg, Amnon

doi:10.1111/apt.13007

Cited by 43 publications

(28 citation statements)

References 26 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chronic active gastritis was defined as the presence of polymorphonuclear cells in the lamina propria in the absence of H. pylori organisms . Chronic inactive gastritis was defined as the presence of dense populations of lymphocytes and plasma cells within the lamina propria, in the absence of activity or H. pylori organisms .…”

Section: Methodsmentioning

confidence: 91%

The coeliac stomach: gastritis in patients with coeliac disease

Lebwohl

Green

Genta

2015

Aliment Pharmacol Ther

Self Cite

View full text Add to dashboard Cite

Background Lymphocytic gastritis (LG) is an uncommon entity with varying symptoms and endoscopic appearances. This condition, as well as two forms of H. pylori-negative gastritis (chronic active gastritis [CAG] and chronic inactive gastritis [CIG]), appears to be more common in patients with coeliac disease (CD) based on single-center studies. Aim To compare the prevalence of LG, CAG, and CIG among those with normal duodenal histology (or non-specific duodenitis) and those with CD, as defined by villous atrophy (Marsh 3). Methods We analyzed all concurrent gastric and duodenal biopsy specimens submitted to a national pathology laboratory during a six-year period. We performed multiple logistic regression to identify independent predictors of each gastritis subtype. Results Among patients who underwent concurrent gastric and duodenal biopsy (n=287,503), the mean age was 52 and the majority (67%) was female. Compared to patients with normal duodenal histology, LG was more common inpartial villous atrophy (OR 37.66; 95% CI 30.16–47.03), and subtotal/total villous atrophy (OR 78.57; 95% CI 65.37–94.44). CD was also more common in CAG (OR for partial villous atrophy 1.93; 95%CI 1.49–2.51, OR for subtotal/total villous atrophy 2.42; 95%CI 1.90–3.09) and was similarly associated with CIG (OR for partial villous atrophy 2.04; 95%CI 1.76–2.35, OR for subtotal/total villous atrophy 2.96; 95% CI 2.60–3.38). Conclusion LG is strongly associated with CD, with increasing prevalence correlating with more advanced villous atrophy. CAG and CIG are also significantly associated with CD. Future researchshould measure the natural history of these conditions after treatment with a gluten-free diet.

show abstract

Section: Methodsmentioning

confidence: 91%

The coeliac stomach: gastritis in patients with coeliac disease

Lebwohl

Green

Genta

2015

Aliment Pharmacol Ther

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, Genta and Sonnenberg based on a pathology database suggested that H. pylori-negative gastritis is, in the vast majority of cases, a nosologically and epidemiologically distinct entity that deserves further investigation. 30 Patients 0 medical history and serology are useful for further characterising patients with H. pylori-negative gastritis. AIG diagnosed in our patients without evidence of current or past H. pylori infection could be included in the group of H. pylori-negative gastritis.…”

Section: Discussionmentioning

confidence: 99%

Autoimmune gastritis in autoimmune thyroid disease

Venerito

Radünz

Reschke

et al. 2015

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Acid suppression with famotidine (0.5 mg/kg q24h) did not affect treatment efficacy or frequency of clinical signs in 23 dogs with histologic evidence of gastritis and spiral bacteria in gastric mucosal biopsy samples . Helicobacter‐negative gastritis can occur in people and may be comparable to idiopathic gastritis in cats and dogs, but no therapeutic regimens have been reported effective for this condition …”

Section: Evidence To Support Clinical Use Of Gastroprotectants In Dogmentioning

confidence: 99%

ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats

Marks

Kook

Papich

et al. 2018

Veterinary Internal Medicne

177

View full text Add to dashboard Cite

The gastrointestinal (GI) mucosal barrier is continuously exposed to noxious toxins, reactive oxygen species, microbes, and drugs, leading to the development of inflammatory, erosive, and ultimately ulcerative lesions. This report offers a consensus opinion on the rational administration of GI protectants to dogs and cats, with an emphasis on proton pump inhibitors (PPIs), histamine type‐2 receptor antagonists (H2RAs), misoprostol, and sucralfate. These medications decrease gastric acidity or promote mucosal protective mechanisms, transforming the management of dyspepsia, peptic ulceration, and gastroesophageal reflux disease. In contrast to guidelines that have been established in people for the optimal treatment of gastroduodenal ulcers and gastroesophageal reflux disease, effective clinical dosages of antisecretory drugs have not been well established in the dog and cat to date. Similar to the situation in human medicine, practice of inappropriate prescription of acid suppressants is also commonplace in veterinary medicine. This report challenges the dogma and clinical practice of administering GI protectants for the routine management of gastritis, pancreatitis, hepatic disease, and renal disease in dogs and cats lacking additional risk factors for ulceration or concerns for GI bleeding. Judicious use of acid suppressants is warranted considering recent studies that have documented adverse effects of long‐term supplementation of PPIs in people and animals.

show abstract

Helicobacter‐negative gastritis: a distinct entity unrelated to Helicobacter pylori infection

Cited by 43 publications

References 26 publications

The coeliac stomach: gastritis in patients with coeliac disease

The coeliac stomach: gastritis in patients with coeliac disease

Autoimmune gastritis in autoimmune thyroid disease

ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats

Contact Info

Product

Resources

About